Q-omics provides the consensus-scored SCARNA18B profile across patient tissues and cancer cell-line models. SCARNA18B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SCARNA18B is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, SCARNA18B RNA expression shows 7,364 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, STAD, and LSCC as cancer lineages where SCARNA18B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARNA18B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARNA18B survival associations across molecular data types. SCARNA18B RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARNA18B RNA expression–survival associations across cancer types. High SCARNA18B expression shows unfavorable associations in MESO, UVM and KIRC, but favorable associations in STAD, COAD and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SCARNA18B RNA expression.
This table summarizes SCARNA18B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for SCARNA18B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARNA18B shows lower tumor expression in COAD and higher tumor expression in STAD and LUAD. The STAD box plot shows higher SCARNA18B RNA expression in tumor versus normal tissue (log2 FC = +0.199, t-test p = .013).
This table shows molecular features associated with SCARNA18B in patient tissues and cancer cell lines. In patient samples, SCARNA18B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
